Budget 2021: Govt proposes Rs 20,000 crore recapitalisation for PSBs

Budget 2021: Govt proposes Rs 20,000 crore recapitalisation for PSBs

PTIUpdated: Monday, February 01, 2021, 04:24 PM IST
article-image

Finance Minister Nirmala Sitharaman on Monday said the government would infuse Rs 20,000 crore into public sector banks (PSBs) in 2021-22, to meet the regulatory norms.

For the current financial year also, the government had made a provision of Rs 20,000 crore for recapitalisation.

Unveiling the Budget 2021-22 in the Lok Sabha, the finance minister said the government has proposed to infuse Rs 20,000 crore into the PSBs, to further consolidate financial health of banks.

During 2019-20, the government had proposed to make a Rs 70,000-crore capital infusion into the PSBs to boost credit for a strong impetus to the economy.

However, the government refrained from committing any capital for the PSBs in the Budget 2020-21, hoping that the lenders will raise funds from the market depending on the requirements.

Later, in September 2020, Parliament approved Rs 20,000 crore capital infusion for PSBs as part of the first batch of Supplementary Demands for Grants for 2020-21.

Of this, the government provided Rs 5,500 crore to Punjab & Sind Bank in November 2020, to meet the regulatory capital requirement.

In 2017-18, the government had infused Rs 90,000 crore, followed by Rs 1.06 lakh crore in 2018-19.

RECENT STORIES

Meta Shares Crash Over 10% As Anxiety Over Success Of AI Surges

Meta Shares Crash Over 10% As Anxiety Over Success Of AI Surges

Land Rover Defender Octa: Most Powerful Version Set to Debut on July 3rd

Land Rover Defender Octa: Most Powerful Version Set to Debut on July 3rd

UK-TIK TOK Ban: How Other Countries are Restricting it

UK-TIK TOK Ban: How Other Countries are Restricting it

Shriram Finance Q4 Results Announces a 150% Dividend, 450% Dividend in a Year

Shriram Finance Q4 Results Announces a 150% Dividend, 450% Dividend in a Year

Opioid Overkill: McKinsey Under Probe For Maximizing Sale Of Drugs

Opioid Overkill: McKinsey Under Probe For Maximizing Sale Of Drugs